Clinical Research Directory

Inclusion Criteria: * Signed informed consent; * Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV); * Age 18-75 years; * Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months); Exclusion Criteria: * Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment; * Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time; * Combined with other malignant tumors, still receiving anti-tumor therapy; * Has any other active disease that may increase the risk of protocol therapy or impair the patient\'s ability to receive protocol therapy, including but not limited to: * Comorbid epilepsy; * Comorbid autoimmune diseases; * Combined with hepatic decompensation; * Patients with renal insufficiency and creatinine clearance \< 50ml/min; * Have an uncontrollable medical condition, including but not limited to: * Ongoing or active infection; * Clinically significant healing or non-healing wounds; * Symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias; * Significant lung disease (e.g., shortness of breath at rest or light activity, or need for supplemental oxygen for any reason); * Diseases/conditions that affect study compliance, such as infectious diseases or psychiatric illnesses/social situations, that are uncontrollable; * Pregnant (or intending to become pregnant within 2 years) or lactating females; * Concomitant participation in interventional clinical trials of other clinical trial drugs, except for questionnaire surveys or observational studies; * Any situation in which the programme is not in compliance; * Other conditions that in the opinion of the investigator are not suitable for participation in this study.